11,077 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by &Partners

&Partners purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the first quarter, HoldingsChannel reports. The fund purchased 11,077 shares of the company’s stock, valued at approximately $154,000.

Other hedge funds also recently made changes to their positions in the company. Rise Advisors LLC bought a new stake in shares of Takeda Pharmaceutical in the first quarter worth $26,000. GAMMA Investing LLC bought a new stake in Takeda Pharmaceutical during the 4th quarter worth about $28,000. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth about $28,000. First United Bank & Trust bought a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $29,000. Finally, Lindbrook Capital LLC increased its position in shares of Takeda Pharmaceutical by 40.6% in the fourth quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock valued at $58,000 after acquiring an additional 1,174 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $12.88 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.58 and a current ratio of 1.11. The stock has a 50 day moving average price of $13.18 and a 200 day moving average price of $13.92. The stock has a market capitalization of $40.76 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 0.35 and a beta of 0.55. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $16.39.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.